Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
15 sept. 2024 08h45 HE
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
10 sept. 2024 16h06 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; September 10, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 11,729 shares as a consequence of the exercise of employee warrants. The...
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
26 août 2024 12h26 HE
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; August 26, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will...
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
19 août 2024 14h00 HE
|
Genmab A/S
Company Announcement TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma...
Genmab Announces Changes to its Executive Committee
16 août 2024 09h00 HE
|
Genmab A/S
Media Release COPENHAGEN, Denmark; August 16, 2024 Rayne Waller joins as Executive Vice President and Chief Technology OfficerBrad Bailey appointed as Executive Vice President and Chief...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
13 août 2024 14h53 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
13 août 2024 14h51 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,193 shares as a consequence of the exercise of employee warrants. The...
Genmab Announces Financial Results for the First Half of 2024
08 août 2024 11h03 HE
|
Genmab A/S
August 8, 2024 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2024 Highlights Completed acquisition of ProfoundBio Inc (ProfoundBio), granting Genmab worldwide rights to...
Genmab Updates 2024 Financial Guidance
08 août 2024 11h00 HE
|
Genmab A/S
Company Announcement Genmab updates its 2024 financial guidanceIncrease in revenue driven by higher royalties and reimbursement revenueIncrease in operating profit excluding acquisition and...
Genmab Takes Full Control of Acasunlimab Development Program
05 août 2024 05h50 HE
|
Genmab A/S
Company Announcement Genmab to assume sole responsibility for the continued development and potential commercialization of acasunlimab BioNTech has opted not to participate in the further development...